1. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

   • Xavier Cahu
   • Stefan N. Constantinescu

   Myeloproliferative Disorders (C Harrison, Section Editor) 14 September 2015 Pages: 335 - 343

   

2. Current Challenges in Stem Cell Transplantation in Myelofibrosis

   • Nicolaus Kröger

   Myeloproliferative Disorders (C Harrison, Section Editor) 19 August 2015 Pages: 344 - 350

3. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis

   • Jason Gotlib

   Myeloproliferative Disorders (C Harrison, Section Editor) 24 September 2015 Pages: 351 - 361

   

4. Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis

   • Giovanni Barosi

   Myeloproliferative Disorders (C Harrison, Section Editor) 16 August 2015 Pages: 362 - 369

5. Immunological Consequences of JAK Inhibition: Friend or Foe?

   • Donal P. McLornan
   • Alesia A. Khan
   • Claire N. Harrison

   Myeloproliferative Disorders (C Harrison, Section Editor) 21 August 2015 Pages: 370 - 379

   

6. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

   • Paola Guglielmelli
   • Giada Rotunno
   • Alessandro Maria Vannucchi

   Myeloproliferative Disorders (C Harrison, Section Editor) 02 October 2015 Pages: 380 - 387

7. Novel Induction Regimens in Multiple Myeloma

   • Karie D. Runcie
   • Tomer M. Mark

   Multiple Myeloma (R Nievszky, Section Editor) 15 August 2015 Pages: 388 - 394

8. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies

   • Rebecca Karp Leaf
   • Hearn Jay Cho
   • David Avigan

   Multiple Myeloma (R Nievszky, Section Editor) 04 September 2015 Pages: 395 - 404

9. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider

   • Michael A. Thompson
   • Navneet S. Majhail
   • Mélanie Chaboissier

   Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 09 October 2015 Pages: 405 - 412

   

10. Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM

    • Naveen Pemmaraju
    • Vikas Gupta
    • Michael A. Thompson

    Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 28 September 2015 Pages: 413 - 420

11. Mature T-cell leukemias: Molecular and Clinical Aspects

    • Nathanael G. Bailey
    • Kojo S. J. Elenitoba-Johnson

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 03 October 2015 Pages: 421 - 428

12. Molecular Pathogenesis of Peripheral T Cell Lymphoma

    • Mamiko Sakata-Yanagimoto
    • Shigeru Chiba

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 02 October 2015 Pages: 429 - 437

    

13. Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

    • Jonathan Hebb
    • Holbrook Kohrt

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 03 October 2015 Pages: 438 - 447

    

14. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project

    • Monica Bellei
    • Chadi Nabhan
    • Massimo Federico

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 08 October 2015 Pages: 448 - 455

15. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment

    • A. A. Gru
    • B. H. Haverkos
    • P. Porcu

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 08 October 2015 Pages: 456 - 467

16. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy

    • Catherine G. Chung
    • Brian Poligone

    T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 01 December 2015 Pages: 468 - 476